<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04452435</url>
  </required_header>
  <id_info>
    <org_study_id>VP-C21-006</org_study_id>
    <secondary_id>2020-001502-38</secondary_id>
    <nct_id>NCT04452435</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of C21 in Subjects With COVID-19</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Phase 2 Trial Investigating the Safety and Efficacy of C21 in Hospitalised Subjects With COVID-19 Infection Not Requiring Mechanical Ventilation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vicore Pharma AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Orphan Reach</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vicore Pharma AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised, double-blind, placebo-controlled phase 2 trial investigating the safety
      and efficacy of C21 in subjects who are hospitalised with COVID-19 infection, but not in need
      of mechanical invasive or non-invasive ventilation.

      In total, approximately 100 subjects will be enrolled and randomised to receive twice daily
      oral administration of either standard of care (SoC) + placebo (N=50) or SoC + C21 (N=50).
      Subjects will be treated for 7 days.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 21, 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in C-reactive protein (CRP) after treatment with C21 200 mg daily dose (100 mg b.i.d.)</measure>
    <time_frame>Treatment period of 7 days</time_frame>
    <description>Primary endpoint</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>C21</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C21</intervention_name>
    <description>C21</description>
    <arm_group_label>C21</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent, consistent with ICH-GCP R2 and local laws, obtained before
             the initiation of any trial related procedure

          2. Diagnosis of coronavirus (SARS-CoV)-2 infection confirmed by polymerase chain reaction
             (PCR) test &lt; 4 days before Visit 1 with signs of an acute respiratory infection

          3. Age &gt; 18 and &lt; 70 years

          4. CRP &gt; 50 and &lt; 150 mg/l

          5. Admitted to a hospital or controlled facility (home quarantine is not sufficient)

          6. In the opinion of the Investigator, the subject will be able to comply with the
             requirements of the protocol

        Exclusion Criteria:

          1. Any previous experimental treatment for COVID-19

          2. Need for mechanical invasive or non-invasive ventilation

          3. Concurrent respiratory disease such as COPD (chronic obstructive pulmonary disease),
             IPF and/or intermittent, persistent or more severe asthma requiring daily therapy or
             any subjects that have had an asthma flare requiring corticosteroids in the 4 weeks
             (28 days) prior to COVID-19 diagnosis

          4. Participation in any other interventional trial within 3 months prior to Visit 1

          5. Any of the following findings at Visit 1:

               -  Positive results for hepatitis B surface antigen (HBsAg), hepatitis C virus
                  antibody (HCVAb) or human immunodeficiency virus 1+2 antigen/antibody (HIV 1+2
                  Ag/Ab

               -  Positive pregnancy test (see Section 8.2.3)

          6. Clinically significant abnormal laboratory value at Visit 1 indicating a potential
             risk for the subject if enrolled in the trial as evaluated by the Investigator

          7. Concurrent serious medical condition with special attention to cardiac or ophthalmic
             conditions (e.g. contraindications to cataract surgery), which in the opinion of the
             Investigator makes the subject inappropriate for this trial

          8. Malignancy within the past 3 years with the exception of in situ removal of basal cell
             carcinoma and cervical intraepithelial neoplasia grade I

          9. Treatment with any of the medications listed below within 1 week prior to Visit 1:

               1. Strong Cytochrome p450 (CYP) 3A4 inducers (e.g. rifampicin, phenytoin, St. John's
                  Wort, phenobarbital, rifabutin, carbamazepine, anti HIV drugs, barbituates)

               2. Warfarin

         10. Pregnant or breast-feeding female subjects

         11. Female subjects of childbearing potential not willing to use contraceptive methods as
             described in Section 5.3.1

         12. Male subjects not willing to use contraceptive methods as described in Section 5.3.1

         13. Subjects known or suspected of not being able to comply with this trial protocol (e.g.
             due to alcoholism, drug dependency or psychological disorder)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanna Porter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Respiratory Medicine, University College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mimi Flensburg, DVM PhD</last_name>
    <phone>+45 2210 9950</phone>
    <email>mimi.flensburg@vicorepharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Medicine, Civil Hospital and B J Medical College</name>
      <address>
        <city>Ahmadabad</city>
        <state>Gujarat</state>
        <zip>380016</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kartikeya Parmar, MD</last_name>
      <phone>9924643799</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Infectious Disease, Metas Adventist Hospital</name>
      <address>
        <city>Surat</city>
        <state>Gujarat</state>
        <zip>395001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chirag Chhatwani, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Department, Basement, Unity Trauma Centre and ICU (Unity Hospital</name>
      <address>
        <city>Surat</city>
        <state>Gujarat</state>
        <zip>395010</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahesh Sutariya, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Floor Clinical Research Department Rhythm Heart Institute</name>
      <address>
        <city>Vadodara</city>
        <state>Gujarat</state>
        <zip>290022</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nirav Bhalani, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Internal Medicine S.L. Raheja Hospital</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400016</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paritosh Baghel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Medicine, Government Medical College and Hospital</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440003</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Atul Rajkondawar, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neuro Critical Care, Grant Medical Foundation Ruby Hall Clinic</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kapil Zirpe, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Medicine, Noble Hospitals Pvt. Ltd</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reema Kashiva, MD</last_name>
      <phone>9922618286</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Respiratory Medicine, University College Hospital</name>
      <address>
        <city>London</city>
        <zip>WC1E 6BT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Porter, MD</last_name>
      <phone>+44 0203 4479004</phone>
      <email>UCLH.respiratorymedicine@nhs.net</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 29, 2020</study_first_submitted>
  <study_first_submitted_qc>June 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2020</study_first_posted>
  <last_update_submitted>August 31, 2020</last_update_submitted>
  <last_update_submitted_qc>August 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

